TY - JOUR
T1 - Lipoproteins and lipids in cardiovascular disease
T2 - from mechanistic insights to therapeutic targeting
AU - Soppert, Josefin
AU - Lehrke, Michael
AU - Marx, Nikolaus
AU - Jankowski, Joachim
AU - Noels, Heidi
N1 - Funding Information:
This work was supported by the German Research Foundation ( DFG SFB/TRR219-M05 to H.N. and N.M.; SFB/TRR219-M03 to M.L. and N.M.; SFB/TRR219-C04 and S-03 to J.J. ; DFG/CRC1382 A-04 to J.J. and H.N.); by the CORONA foundation (to M.L., N.M. and J.J.) and by the Interreg V-A EMR program (EURLIPIDS, EMR23 to M.L., N.M. and J.J.).
Publisher Copyright:
© 2020 The Authors
PY - 2020
Y1 - 2020
N2 - With cardiovascular disease being the leading cause of morbidity and mortality worldwide, effective and costefficient therapies to reduce cardiovascular risk are highly needed. Lipids and lipoprotein particles crucially contribute to atherosclerosis as underlying pathology of cardiovascular disease and influence inflammatory processes as well as function of leukocytes, vascular and cardiac cells, thereby impacting on vessels and heart. Statins form the first-line therapy with the aim to block cholesterol synthesis, but additional lipid-lowering drugs are sometimes needed to achieve low-density lipoprotein (LDL) cholesterol target values. Furthermore, beyond LDL cholesterol, also other lipid mediators contribute to cardiovascular risk. This review comprehensively discusses low- and high-density lipoprotein cholesterol, lipoprotein (a), triglycerides as well as fatty acids and derivatives in the context of cardiovascular disease, providing mechanistic insights into their role in pathological processes impacting on cardiovascular disease. Also, an overview of applied as well as emerging therapeutic strategies to reduce lipid-induced cardiovascular burden is provided. (C) 2020 The Author(s). Published by Elsevier B.V.
AB - With cardiovascular disease being the leading cause of morbidity and mortality worldwide, effective and costefficient therapies to reduce cardiovascular risk are highly needed. Lipids and lipoprotein particles crucially contribute to atherosclerosis as underlying pathology of cardiovascular disease and influence inflammatory processes as well as function of leukocytes, vascular and cardiac cells, thereby impacting on vessels and heart. Statins form the first-line therapy with the aim to block cholesterol synthesis, but additional lipid-lowering drugs are sometimes needed to achieve low-density lipoprotein (LDL) cholesterol target values. Furthermore, beyond LDL cholesterol, also other lipid mediators contribute to cardiovascular risk. This review comprehensively discusses low- and high-density lipoprotein cholesterol, lipoprotein (a), triglycerides as well as fatty acids and derivatives in the context of cardiovascular disease, providing mechanistic insights into their role in pathological processes impacting on cardiovascular disease. Also, an overview of applied as well as emerging therapeutic strategies to reduce lipid-induced cardiovascular burden is provided. (C) 2020 The Author(s). Published by Elsevier B.V.
KW - Cardiovascular disease
KW - atherosclerosis
KW - myocardial infarction
KW - lipid
KW - HDL
KW - LDL
KW - triglyceride
KW - fatty acid
KW - lipoprotein(a)
KW - lipid-lowering therapy
KW - HIGH-DENSITY-LIPOPROTEIN
KW - CORONARY-HEART-DISEASE
KW - APOLIPOPROTEIN-A-I
KW - SERUM-AMYLOID-A
KW - HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
KW - NITRIC-OXIDE SYNTHASE
KW - PLATELET-ACTIVATING-FACTOR
KW - LECITHIN-CHOLESTEROL ACYLTRANSFERASE
KW - TRIGLYCERIDE-TRANSFER PROTEIN
KW - EXTENDED-RELEASE NIACIN
U2 - 10.1016/j.addr.2020.07.019
DO - 10.1016/j.addr.2020.07.019
M3 - (Systematic) Review article
C2 - 32730849
SN - 0169-409X
VL - 159
SP - 4
EP - 33
JO - Advanced Drug Delivery Reviews
JF - Advanced Drug Delivery Reviews
ER -